#United States #Las Vegas #VIVA Foundation #VEINS #venous disease

Exciting Insights from VEINS 2025

The annual VEINS 2025 conference, held at the luxurious Wynn Las Vegas, recently unveiled groundbreaking clinical trial results that promise to reshape the understanding and treatment of venous diseases. Organized by the VIVA Foundation, which is dedicated to enhancing vascular medicine through research and education, this event gathered top experts from around the world to share the latest clinical data and innovative strategies in venous interventions.

Key Presentations at the Conference

GORE® VIABAHN® FORTEGRA Venous Stent Clinical Trial

One of the standout presentations was by Dr. Stephen Black, showcasing results from a significant clinical trial focusing on the GORE® VIABAHN® FORTEGRA venous stent aimed at treating symptomatic inferior vena cava obstruction. This landmark trial involved 89 patients suffering from complex venous conditions and demonstrated remarkable results. The stent achieved a stunning 12-month primary patency rate of 83.4%, with outstanding vessel-specific patency rates of 96.5% in the inferior vena cava. This represents a vital advancement in device technology for treating deep venous obstruction, reinforcing the importance of ongoing innovation in vascular treatments.

Spectrum Program: A Comparison of Treatment Methods

Dr. Manj Gohel presented findings from a randomized trial assessing cyanoacrylate closure versus endothermal ablation for saphenous reflux. This extensive study, involving 17 sites across eight nations, revealed that while both treatment options are effective, cyanoacrylate closure may provide better early quality of life improvements. Despite differences in short-term results, the long-term effectiveness of both methods remains comparable, bolstering treatment options for venous insufficiency patients.

Novel Device for Chronic Venous Insufficiency Treatment

Dr. Steve Elias introduced a groundbreaking study utilizing a new device for treating chronic venous insufficiency of the lower limb. In a prospective trial involving 28 patients, the device demonstrated a 100% technical success rate for great saphenous vein occlusion, marking a significant step toward improving procedural safety in this patient population.

JURY-2 Study on Junctional Reflux

Another pivotal presentation from Dr. Yana Etkin assessed the impact of isolated great saphenous vein reflux on treatment outcomes. The study highlighted that patients without saphenofemoral junction involvement often experience symptom severity comparable to those with combined reflux. These findings have significant implications for insurance reimbursement policies, prompting calls for reform based on clinical necessity rather than anatomical considerations.

Economic Analysis of Treatment Options

Dr. Samuel Horr presented a cost-effectiveness analysis of large-bore mechanical thrombectomy versus catheter-directed thrombolysis for intermediate-risk pulmonary embolism. Insights from the PEERLESS trial indicated that LBMT represents a more economical choice, saving nearly $4,755 per patient while improving quality of life outcomes.

Conclusion

The VEINS 2025 conference served as a significant platform for sharing vital advancements in vascular medicine. The trial results presented not only advance the current understanding of venous disease management but also provide valuable insights into the economic aspects of treatment innovations. As the field continues to evolve, such collaborations among experts will be essential in promoting effective and cost-efficient care for patients with vascular conditions. For more information on the VIVA Foundation and ongoing initiatives in vascular medicine, visit their official website at https://viva-foundation.org/.